Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge
STOCKHOLM, November 30[th], 2020 – Moberg Pharma AB (publ) (”Moberg Pharma” or the ”Company”) has obtained a positive decision confirming that the Swedish Tax Agency shares the Company’s assessment that the Company’s proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, which means that the distribution will not be subject to taxation for the Company’s shareholders.The board of directors of Moberg Pharma has proposed that the extraordinary general meeting to be held tomorrow, 1 December 2020,